Fosun Pharma to pay $240 million for Alma Lasers

Fosun Pharma and Pramerica-Fosun China Opportunity Fund intend to buy a leading Israeli aesthetic medical devices manufacturer.

Fosun Pharma to pay $240 million for Alma Lasers

Shanghai Fosun Pharma, the subsidiary of Fosun International, and Pramerica-Fosun China Opportunity Fund will pay $240 million for up to 95.6% of Israel-based Alma Lasers.

It is Fosun Pharma’s first international healthcare acquisition since its Hong Kong H-share listing in October last year. According to IMS Health Incorporated, Fosun was one of the top five domestic companies in China by revenue in the pharmaceutical manufacturing segment in 2011.

China is one...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Print Edition

FinanceAsia Print Edition

EVENTS